Sources

10 Total Sources

Biogen Advances BIIB080 After 26% Slower Alzheimer’s Decline Despite Phase 2 Trial Failure

Left50%

Center33%

Right17%

BioPharma Dive3d ago

Biogen's BIIB080 Trial Shows 26% Slower Alzheimer's Decline; Advances Tau-Targeting Drug

Biogen Alzheimer's drug slowed cognitive decline in midstage study

Biogen's Alzheimer's drug lowers toxic protein, but results were mixed | The Mighty 790 KFGO | KFGO

abcnews.com3d ago

Biogen's Diranersen Shows Promise in Slowing Early Alzheimer's by Lowering Tau Protein

The Associated Press3d ago

Biogen's Diranersen Shows Promise in Early Alzheimer's by Lowering Tau Protein

StockTitan3d ago

Biogen Diranersen Phase 2 Shows 50% MMSE Slowing | BIIB Stock News

Endpoints News3d ago

Biogen's tau drug reports mixed Alzheimer's results, as low dose performs better

Fierce Biotech3d ago

AAIC: Biogen bolsters hopes for pivotal anti-tau push

An experimental Alzheimer's drug shows some promise as researchers hunt new approaches - Newsday

Biogen | Investor Relations3d ago

Biogen's Diranersen Phase 2 CELIA Data Shows 26% Slower Alzheimer's Decline, 50-65% Tau Reduction